Camel of Israel, November 3, 2026 / PRNewswire / -- Protalix BioTherapeutics, Inc. (New York Stock Exchange US market code: PLX) is a biopharmaceutical company focused on discovering, developing, producing, and commercializing innovative therapies for rare diseases. The company announced today that it will release its financial results for the quarter ending September 30, 2026, on November 10, 2026, and provide business updates as well.

Management will hold a teleconference to discuss financial performance and provide an update on recent company and regulatory developments.

Teleconference Information:

• Date: Tuesday, November 10, 2026
• Time: 8:00 a.m. Eastern Time, USA
• US toll-free phone: 1-877-423-9813
• International phone number: 1-201-689-8573
• Israel Free Phone: 1-809-406-247
• Meeting Number: 13763420
• Call me ™: https :// tinyurl.com /3awxvdvm

Call me ™ This feature allows participants to avoid waiting for operators; after users enter a phone number on the platform, the system will dial back immediately.

Live streaming information:

The teleconference will be live-streamed via the Protalix website, and can be watched through the following links:

• Company links: https :// ir.protalix.com / news-events / events
• Live streaming link: https :// tinyurl.com / ye6k6b3n
• Meeting Number: 13763420

The company reminds participants to connect at least 15 minutes before the meeting begins in order to complete registration and download and install the necessary audio software. The recording of the teleconference will be available for two weeks in the event calendar under the investor section of the company's website; the link is the same as above.

Regarding Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative therapies for rare diseases. The company has researched, developed, and is currently producing two enzyme replacement therapies, which are already available on multiple markets. These therapies consist of recombinant therapeutic proteins expressed through Protalix's proprietary plant cell expression system, ProCellEx ®. ProCellEx is a unique plant cell system that enables Protalix to produce recombinant proteins on an industrial scale without involving mammalian cells. Protalix is the first company to receive approval from the U.S. Food and Drug Administration (FDA) to produce proteins using a suspended expression plant cell system.

Protalix has granted the global development and commercialization rights of taliglucerase alfa ( Elelyso ®) to Pfizer for the treatment of Gaucher's disease, except in Brazil, where the company retains all rights.

Protalix also collaborates with Chiesi Farmaceutici S and p.A to jointly advance the global development and commercialization of Elfabrio ®. This drug was approved by FDA and the European Medicines Agency (EMA) in May 2023. The company's R&D pipeline also includes two proprietary recombinant therapeutic protein versions targeting mature pharmaceutical markets: PRX-115, a plant cell-expressed recombinant PEG uricase for the treatment of uncontrolled gout; and PRX-119, a plant cell-expressed long-acting DNase I for the treatment of diseases related to NETs. For more information, please visit www.protalix.com.

Investor Contact

Mike Moyer, Managing Director